Deutsche Telekom and LG Back A.I. Medical Assistant Tandem Health

Tandem Health has brought in three strategic investors as part of its Series B: T.Capital, LG Technology Ventures and Norrsken VC. The Stockholm company says the match was deliberate. Each backer already has reach in the healthcare systems Tandem wants to sell into. The money terms were not disclosed.

Deutsche Telekom matters here because of Germany. Tandem points to T-Systems’ medical record systems in more than 250 hospitals and over 100,000 users, and Germany’s tangled, privacy-heavy market is one of the hardest places in Europe to sell clinical AI. LG is supposed to open customer doors across Europe. Norrsken brings impact credentials and its own KPI framework for portfolio companies.

The pitch is simple enough: doctors and nurses spend around 40% of their working time on administration, so Tandem’s assistant sits in on consultations, writes the documentation, codes diagnoses and procedures, and offers decision support. Three products are already certified as Class IIa medical devices under EU rules, and LG says about half the team are clinicians.

The company has been moving fast. It raised $50 million in a Series A last year, then another $100 million in September in a round led by the European Commission’s Scaleup Europe Fund, managed by EQT. Including that money, Tandem says it has raised about $160 million. It now says 10,000 care organizations in 14 countries use its software, among them Britain’s NHS, Ramsay Santé and Humanitas, and it connects to more than 130 medical record systems. Earlier this year it also bought the Dutch AI scribe Juvoly.

Tandem wants to go well beyond note-taking. Its stated aim is to give European clinicians one billion hours back and turn itself into an “AI-native clinic operating system” covering scheduling, patient flow and administration. That puts it in a crowded field, with rivals such as Nabla, Noteless, Heidi Health, Abridge and Microsoft’s Dragon Copilot. But Tandem is betting that Europe’s love of paperwork and regulation can be turned into a moat, not a headache.